The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine

Advertisement

Advertise with us

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine that could be used to treat bird flu in people, as concern grows about cases in dairy cows across the country, federal officials announced Tuesday.

Read this article for free:

or

Already have an account? Log in here »

To continue reading, please subscribe:

Monthly Digital Subscription

$0 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.

Monthly Digital Subscription

$4.75/week*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*Billed as $19 plus GST every four weeks. Cancel any time.

To continue reading, please subscribe:

Add Free Press access to your Brandon Sun subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles
Start now

No thanks

*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.

Hey there, time traveller!
This article was published 02/07/2024 (522 days ago), so information in it may no longer be current.

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine that could be used to treat bird flu in people, as concern grows about cases in dairy cows across the country, federal officials announced Tuesday.

Moderna already has a bird flu vaccine in very early-stage testing that uses the same mRNA technology that allowed rapid development and rollout of vaccines to protect against COVID-19. The new funds from the U.S. Department of Health and Human Services include continued development of the vaccine, including a late-stage trial next year if those early study results are positive.

But the project can be quicky redirected to target another form of influenza if a different threat than the H5N1 form of bird flu emerges, HHS officials stressed.

FILE - A patient is given a flu vaccine Oct. 28, 2022, in Lynwood, Calif. On Tuesday, July 2, 2024, the U.S. Department of Health and Human Services announced plans to pay Moderna $176 million to develop a mRNA vaccine to treat bird flu in people, as cases in dairy cows continue to mount across the country. (AP Photo/Mark J. Terrill, File)
FILE - A patient is given a flu vaccine Oct. 28, 2022, in Lynwood, Calif. On Tuesday, July 2, 2024, the U.S. Department of Health and Human Services announced plans to pay Moderna $176 million to develop a mRNA vaccine to treat bird flu in people, as cases in dairy cows continue to mount across the country. (AP Photo/Mark J. Terrill, File)

The award was made through the Biomedical Advanced Research and Development Authority, or BARDA, a program that focuses on medical treatments for potential pandemics.

The H5N1 virus was detected earlier this year in dairy cows and has spread to more than 135 herds in 12 states and infected three people to date, all with mild cases. Federal health officials stress that the risk to the wider population remains low.

__

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Report Error Submit a Tip